X-linked G6PD Deficiency - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html X‑linked G6PD Deficiency – Complete Medical Guide

X‑linked Glucose‑6‑Phosphate Dehydrogenase (G6PD) Deficiency

Overview

Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency is the most common enzymatic disorder of red blood cells worldwide. It is an X‑linked recessive condition caused by mutations in the G6PD gene that reduce the activity of the G6PD enzyme, a key player in protecting red blood cells from oxidative damage. Because the gene resides on the X chromosome, males (who have only one X) are usually affected, while females are typically carriers; however, due to X‑inactivation, some females can develop clinically significant hemolysis.

According to the World Health Organization (WHO), an estimated 400 million people are affected globally, making it the most prevalent hereditary enzymopathy. Prevalence varies by ethnicity:

  • African‑American males: 10–14 %
  • Middle‑Eastern and South‑Asian males: 5–20 %
  • Mediterranean (e.g., Greek, Italian) males: 2–14 %
  • East Asian populations: <1 %

Most individuals are asymptomatic until exposed to a trigger that increases oxidative stress (e.g., certain foods, medications, infections). When hemolysis occurs, patients may develop a spectrum of symptoms ranging from mild fatigue to life‑threatening anemia.

Symptoms

Symptoms are episodic and usually appear 1–3 days after exposure to a trigger. The classic presentation is acute hemolytic anemia, but milder signs may also be present.

Acute hemolysis

  • Fatigue and weakness: Result from reduced oxygen‑carrying capacity.
  • Pallor: Noticeable in the face, lips, and nail beds.
  • Jaundice: Yellowing of the skin and sclera due to elevated bilirubin.
  • Dark urine (cola‑colored): Hemoglobinuria from free hemoglobin filtered by kidneys.
  • Back or abdominal pain: Related to splenic enlargement or renal colic.
  • Rapid heart rate (tachycardia) and shortness of breath: Compensatory response to anemia.
  • Fever: Often seen with infection‑triggered hemolysis.

Chronic or sub‑clinical findings

  • Low baseline hemoglobin (mild anemia) without obvious episodes.
  • Elevated reticulocyte count (bone‑marrow response to chronic RBC turnover).
  • Gallstones (pigment stones) due to chronic bilirubin overproduction.
  • Splenomegaly in severe or repeated hemolysis.

Neonatal manifestations

  • Jaundice within the first 24‑48 hours of life.
  • Risk of bilirubin‑induced neurologic dysfunction (kernicterus) if not treated promptly.

Causes and Risk Factors

The underlying cause is a genetic mutation that reduces G6PD enzyme activity. Over 400 variants have been identified; they are classified by residual enzyme activity:

  • Class I: <10 % activity with chronic non‑spherocytic hemolytic anemia.
  • Class II: <10 % activity, severe hemolysis with triggers.
  • Class III: 10–60 % activity, moderate hemolysis.
  • Class IV: >60 % activity, usually asymptomatic.

Risk factors for an episode

  • Oxidative drugs: Primaquine, sulfamethoxazole‑trimethoprim, dapsone, nitrofurantoin, certain antibiotics, and high‑dose vitamin C.
  • Foods: Fava beans (favism), broad‑leaf legumes.
  • Infections: Viral (e.g., hepatitis, influenza) or bacterial infections increase oxidative stress.
  • Chemicals: Naphthalene (mothballs), certain industrial oxidants.
  • Metabolic stress: Severe dehydration, rapid weight loss, or intense physical exertion.

Diagnosis

Diagnosis combines clinical suspicion with laboratory testing.

1. Screening tests

  • Quantitative G6PD enzyme assay: Measures enzyme activity in red blood cells. Results are reported as units per gram of hemoglobin (U/g Hb) or as a percentage of normal activity. Values < 60 % of normal are abnormal.
  • Fluorescent spot test (FST): A rapid bedside screening that detects NADPH fluorescence; positive (fluorescence) suggests normal activity, while lack of fluorescence raises suspicion.

2. Molecular testing

DNA analysis can identify specific G6PD mutations, useful for carrier detection, prenatal counseling, and epidemiologic studies. Next‑generation sequencing panels are increasingly used.

3. Hemolysis work‑up (during an acute episode)

  • Complete blood count (CBC) – low hemoglobin, high reticulocyte count.
  • Lactate dehydrogenase (LDH) – elevated.
  • Indirect bilirubin – increased.
  • Haptoglobin – decreased (consumed).
  • Urinalysis – positive for hemoglobin.

4. Newborn screening

Many countries (e.g., United States, Saudi Arabia) include G6PD activity in routine heel‑stick panels, enabling early diagnosis and prevention of severe neonatal jaundice.

Treatment Options

There is no cure; management focuses on preventing triggers and treating acute hemolysis.

Acute hemolytic episode

  • Remove the trigger: Discontinue offending drug or food immediately.
  • Hydration: Intravenous (IV) fluids maintain renal perfusion and aid clearance of hemoglobin.
  • Blood transfusion: Reserved for severe anemia (Hb < 7 g/dL), symptomatic tachycardia, or cardiovascular compromise.
  • Folic acid supplementation: 1 mg orally daily accelerates erythropoiesis.
  • Analgesia: Acetaminophen for pain; avoid NSAIDs that may increase oxidative stress.

Chronic management

  • Folic acid (1 mg daily) is recommended for all patients to support red‑cell production.
  • Vitamin E in some studies reduces oxidative stress, though evidence is modest.
  • Vaccination: Annual influenza and pneumococcal vaccines lower infection‑related hemolysis.

Medications to avoid

Clinicians use the WHO G6PD drug chart or the CDC list. Common culprits include:

  • Antimalarials (primaquine, chloroquine, tafenoquine)
  • Sulfonamides and sulfa‑containing antibiotics
  • Quinolones (e.g., ciprofloxacin – high‑dose)
  • Phenazopyridine
  • Some antiretrovirals (e.g., zidovudine)

Living with X‑linked G6PD Deficiency

With proper awareness, most individuals lead normal lives.

Practical daily tips

  • Carry a medical alert card or bracelet indicating G6PD deficiency.
  • Maintain a personal list of unsafe drugs and foods and share it with healthcare providers.
  • Stay hydrated especially during illness, travel, or hot climates.
  • Promptly treat infections with safe antibiotics (e.g., azithromycin) under physician guidance.
  • Educate family and school personnel about the condition and emergency measures.
  • Regular follow‑up (once or twice yearly) to monitor hemoglobin, reticulocyte count, and ferritin.

Travel considerations

When traveling to malaria‑endemic regions, consult a travel‑medicine specialist for alternative prophylaxis (e.g., doxycycline) and bring a written list of prohibited antimalarial agents.

Pregnancy

Women who are carriers should be screened before pregnancy, as hemolysis can be precipitated by infections or certain medications used in prenatal care. Fetal G6PD status is not a direct concern, but maternal health must be maintained.

Prevention

  • Genetic counseling: Recommended for families with known G6PD variants, especially when planning children.
  • Newborn screening: Early identification allows counseling before exposure to triggers.
  • Education on high‑risk foods/drugs: Avoid fava beans and maintain an updated medication list.
  • Vaccination and infection control: Reduces trigger frequency.
  • Regular health checks: Detect subclinical anemia before it becomes severe.

Complications

If hemolysis is recurrent or severe, several complications may arise:

  • Acute kidney injury (AKI): Hemoglobinuria can cause tubular obstruction.
  • Chronic anemia: May lead to fatigue, reduced exercise tolerance, and cardiac strain.
  • Gallstone formation: Pigment stones from chronic bilirubin excess.
  • Hyperbilirubinemia in neonates: Risk of kernicterus and permanent neurologic damage.
  • Splenomegaly: Due to repeated removal of damaged RBCs.
  • Increased oxidative stress: Theoretical link to higher risk of certain cancers; data are limited.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe weakness or dizziness accompanied by rapid heart rate.
  • Dark (cola‑colored) urine or a noticeable decrease in urine output.
  • Significant yellowing of the skin or eyes (jaundice) that develops quickly.
  • Chest pain, shortness of breath at rest, or feeling faint.
  • Severe abdominal or back pain, especially if accompanied by vomiting.
  • High fever (>38.5 °C / 101.3 °F) that does not improve with usual fever‑reducing measures.

These signs may indicate rapid hemolysis, severe anemia, or kidney involvement, all of which require immediate medical intervention.

Key References

  • Mayo Clinic. “G6PD deficiency.” https://www.mayoclinic.org.
  • World Health Organization. “Glucose‑6‑phosphate dehydrogenase deficiency.” WHO Fact Sheet, 2021.
  • Centers for Disease Control and Prevention. “G6PD Deficiency – Clinical Guidance.” CDC.
  • Cleveland Clinic. “G6PD Deficiency: Symptoms, Diagnosis & Treatment.” Cleveland Clinic.
  • National Institutes of Health – National Library of Medicine. “G6PD Deficiency.” MedlinePlus, 2023.
  • Rufer, A. et al. “Management of G6PD deficiency in the era of new antimalarial drugs.” *Lancet Infectious Diseases* 2022;22(7):e245‑e253.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References